Rylaze, Enrylaze(crisantaspase)
Enrylaze (crisantaspase) is an enzyme pharmaceutical. Crisantaspase was first approved as Enrylaze on 2023-09-15. It has been approved in Europe to treat precursor cell lymphoblastic leukemia-lymphoma.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Rylaze
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Asparaginase erwinia chrysanthemi (recombinant)
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Rylaze | asparaginase erwinia chrysanthemi (recombinant)-rywn | Jazz Pharmaceuticals | N-761179 RX | 2021-06-30 | 1 products |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
299 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 40 | 96 | 69 | 14 | 25 | 223 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 37 | 94 | 64 | 16 | 32 | 223 |
| Lymphoid leukemia | D007945 | — | C91 | 36 | 86 | 55 | 14 | 22 | 195 |
| Lymphoma | D008223 | — | C85.9 | 10 | 44 | 20 | 4 | 7 | 81 |
| T-cell lymphoma | D016399 | — | — | 5 | 15 | 2 | 3 | 4 | 27 |
| T-cell lymphoma peripheral | D016411 | — | — | 4 | 13 | 2 | 3 | 4 | 24 |
| Philadelphia chromosome | D010677 | — | — | 4 | 4 | 3 | 2 | — | 11 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 5 | 21 | 12 | — | 1 | 38 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 4 | 7 | 9 | — | — | 20 |
| Myeloid leukemia | D007951 | — | C92 | 3 | 6 | 8 | — | — | 17 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 5 | 9 | 5 | — | — | 16 |
| Recurrence | D012008 | — | — | 6 | 9 | 2 | — | 1 | 15 |
| Extranodal nk-t-cell lymphoma | D054391 | — | C86.0 | 2 | 9 | 1 | — | 3 | 13 |
| Syndrome | D013577 | — | — | 2 | 1 | 6 | — | — | 9 |
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | 1 | 6 | — | — | 9 |
| Acute disease | D000208 | — | — | 3 | 3 | 2 | — | — | 8 |
| Preleukemia | D011289 | — | — | 2 | — | 6 | — | — | 8 |
Show 30 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Biphenotypic leukemia acute | D015456 | — | C95.0 | 2 | 4 | — | — | — | 5 |
| Neoplasms | D009369 | — | C80 | 1 | 4 | — | — | — | 5 |
| Hematologic neoplasms | D019337 | — | — | 2 | 2 | — | — | — | 4 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | 1 | 1 | — | — | 2 | 4 |
| Pancreatitis | D010195 | HP_0001733 | K85 | 1 | 1 | — | — | 1 | 2 |
| T-cell leukemia | D015458 | — | — | 1 | 2 | — | — | — | 2 |
| Precursor b-cell lymphoblastic leukemia-lymphoma | D015452 | — | — | 1 | 2 | — | — | — | 2 |
| Healthy volunteers/patients | — | — | — | — | 1 | — | — | 1 | 2 |
| Urologic neoplasms | D014571 | — | C64-C68 | — | 1 | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
Show 14 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
| Prolymphocytic leukemia t-cell | D015461 | — | C91.6 | 1 | — | — | — | — | 1 |
| Prolymphocytic leukemia | D015463 | — | — | 1 | — | — | — | — | 1 |
| Blast crisis | D001752 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | — | 2 | 2 |
| Ataxia | D001259 | — | R27.0 | — | — | — | — | 1 | 1 |
| Ataxia telangiectasia | D001260 | Orphanet_100 | G11.3 | — | — | — | — | 1 | 1 |
| Telangiectasis | D013684 | — | — | — | — | — | — | 1 | 1 |
| Cerebellar ataxia | D002524 | HP_0001251 | — | — | — | — | — | 1 | 1 |
| T-cell lymphoma cutaneous | D016410 | — | — | — | — | — | — | 1 | 1 |
| Hyperlipidemias | D006949 | HP_0003077 | E78.5 | — | — | — | — | 1 | 1 |
| Hyperlipoproteinemias | D006951 | HP_0010980 | — | — | — | — | — | 1 | 1 |
| Thromboembolism | D013923 | HP_0001907 | — | — | — | — | — | 1 | 1 |
| Residual neoplasm | D018365 | — | — | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Crisantaspase |
| INN | crisantaspase |
| Description | Asparaginase is an enzyme that is used as a medication and in food manufacturing. As a medication, L-asparaginase is used to treat acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available. In food manufacturing it is used to decrease acrylamide.
|
| Classification | Enzyme |
| Drug class | enzymes |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 9015-68-3 |
| RxCUI | 1156 |
| ChEMBL ID | CHEMBL2108931 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00023 |
| UNII ID | D733ET3F9O (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
856 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use